NCLEX Review Guide: Hemolytic-Uremic Syndrome (HUS) in Pediatrics

Disease Process

• Hemolytic-uremic syndrome is characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. The condition involves damage to the endothelial cells of small vessels, leading to platelet activation, fibrin deposition, and formation of microthrombi that cause mechanical hemolysis of red blood cells and obstruction of renal microvasculature.
• The most common form in children is typical or Shiga toxin-associated HUS, which accounts for approximately 90% of pediatric cases and typically follows a gastrointestinal infection with Shiga toxin-producing organisms.

Causative Factors

• Typical HUS (D+ HUS) is most commonly caused by infection with Shiga toxin-producing Escherichia coli (STEC), particularly serotype O157:H7, which is often acquired through consumption of undercooked ground beef, unpasteurized milk, or contaminated produce. Shigella dysenteriae type 1 can also produce Shiga toxin leading to HUS.
• Atypical HUS (aHUS) is rarer and often associated with genetic mutations affecting complement regulation, certain medications, or other underlying conditions. This form is not preceded by diarrhea and has a poorer prognosis than typical HUS.

Presenting Signs & Symptoms

• The prodromal illness typically begins with watery diarrhea that progresses to bloody diarrhea, often accompanied by abdominal pain, vomiting, and low-grade fever. Within 5-10 days after the onset of gastrointestinal symptoms, HUS manifestations develop as the Shiga toxin damages renal endothelial cells.
• Clinical features of established HUS include pallor, fatigue, irritability, decreased urine output (oliguria or anuria), edema, hypertension, and petechiae or purpura due to thrombocytopenia. Neurological symptoms may include irritability, seizures, altered mental status, or stroke in severe cases.

Laboratory Findings

• Complete Blood Count (CBC): Shows evidence of hemolytic anemia with decreased hemoglobin (typically <10 g/dL), elevated reticulocyte count, and thrombocytopenia (platelet count <150,000/μL). The peripheral blood smear reveals schistocytes (fragmented red blood cells), which are characteristic of microangiopathic hemolytic anemia.
• Additional Laboratory Tests: Include elevated blood urea nitrogen (BUN) and creatinine indicating acute kidney injury, elevated lactate dehydrogenase (LDH) from hemolysis, decreased haptoglobin, and negative direct Coombs test. Urinalysis typically shows hematuria, proteinuria, and sometimes pyuria.
• Stool culture and testing for Shiga toxin or Shiga toxin genes should be performed to identify STEC, though results may be negative if collected late in the illness course.

Supportive Care

• The cornerstone of HUS management is supportive care, with careful attention to fluid and electrolyte balance, management of hypertension, and nutritional support. Fluid management is challenging and requires careful monitoring of fluid status, as children may be both hypovolemic from gastrointestinal losses and at risk for fluid overload due to renal impairment.
• Antibiotics are generally contraindicated in suspected STEC infections as they may increase the risk of HUS development by releasing more Shiga toxin from lysed bacteria. However, once HUS is established, antibiotics may be necessary to treat secondary infections.

Renal Replacement Therapy

• Approximately 50-65% of children with HUS require renal replacement therapy (RRT), most commonly in the form of peritoneal dialysis or hemodialysis. Indications for dialysis include severe oliguria or anuria, azotemia, electrolyte imbalances (particularly hyperkalemia), metabolic acidosis, or fluid overload unresponsive to diuretics.
• RRT is typically temporary, with most children recovering renal function within 2-3 weeks. However, some children may develop chronic kidney disease or end-stage renal disease requiring long-term dialysis or kidney transplantation.

Management of Hematologic Complications

• Blood Transfusions are often necessary to treat severe anemia (typically when hemoglobin falls below 6-7 g/dL or if the child is symptomatic). Packed red blood cells should be transfused slowly and in small volumes to avoid fluid overload in the setting of compromised renal function.
• Platelet Transfusions are generally avoided unless there is life-threatening bleeding or an invasive procedure is planned, as transfused platelets may contribute to thrombus formation and potentially worsen microvascular damage.

Assessment & Monitoring

• Perform comprehensive assessment focusing on fluid status, vital signs (especially blood pressure), neurological status, and signs of bleeding. Monitor intake and output strictly, weighing the child daily to assess fluid balance.
• Closely monitor laboratory values including hemoglobin, platelets, electrolytes (particularly potassium), BUN, creatinine, and acid-base status. Assess for signs of complications such as seizures, altered mental status, or respiratory distress.

Nursing Interventions

1. Implement strict infection control measures, including contact precautions for children with active diarrhea, to prevent transmission of STEC.
2. Administer prescribed medications, including antihypertensives and anticonvulsants if needed, while monitoring for effectiveness and side effects.
3. Provide meticulous skin care to prevent breakdown, especially in edematous areas and around catheter sites.
4. Monitor for signs of fluid overload (crackles, increased work of breathing, edema) or dehydration (dry mucous membranes, poor skin turgor).
5. Implement bleeding precautions for thrombocytopenic patients, including avoiding IM injections and using soft toothbrushes.

Family Education

• Provide clear explanations about HUS, its cause, treatment plan, and expected course to the child (age-appropriate) and family. Emphasize that while HUS is serious, most children recover completely with appropriate treatment.
• Educate families about prevention of STEC infections through proper food handling and preparation (cooking ground beef thoroughly, washing produce, avoiding unpasteurized dairy products), hand hygiene, and avoiding cross-contamination in the kitchen.

Acute Complications

• Neurological complications occur in approximately 20-25% of children with HUS and include seizures, altered mental status, stroke, and coma. These complications are associated with higher morbidity and mortality.
• Other acute complications include pancreatic involvement (causing hyperglycemia), cardiac involvement (myocarditis, heart failure), respiratory distress, severe hypertension, and gastrointestinal complications (colonic necrosis, perforation, intussusception).

Long-term Sequelae

• While most children recover completely from HUS, approximately 25-30% develop long-term renal sequelae including proteinuria, hypertension, reduced glomerular filtration rate, or chronic kidney disease. About 3-5% progress to end-stage renal disease requiring long-term dialysis or kidney transplantation.
• Children who experienced severe neurological complications may have persistent neurological deficits, including cognitive impairment, seizure disorders, or motor deficits.

Mortality & Prognosis

• With modern supportive care, the mortality rate for typical HUS has decreased to approximately 3-5%. Deaths are usually associated with severe neurological complications, sepsis, or multi-organ failure.
• Atypical HUS has a poorer prognosis, with higher mortality rates (up to 25% in the acute phase) and higher rates of progression to end-stage renal disease (up to 50% historically, though outcomes have improved with complement inhibitor therapy).

• Hemolytic-uremic syndrome is characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury, most commonly following infection with Shiga toxin-producing E. coli in children.
• Typical HUS usually follows a prodrome of bloody diarrhea by 5-10 days, while atypical HUS lacks this prodrome and has genetic or other causes.
• Diagnostic findings include anemia with schistocytes on peripheral smear, thrombocytopenia, elevated BUN and creatinine, and evidence of hemolysis (elevated LDH, decreased haptoglobin).
• Management is primarily supportive, focusing on fluid and electrolyte balance, blood pressure control, and renal replacement therapy if needed (50-65% of cases).
• Antibiotics are generally contraindicated in suspected STEC infections as they may increase the risk of HUS development.
• Nursing care focuses on careful monitoring of fluid status, neurological assessment, and prevention of complications.
• Most children recover completely, but 25-30% develop long-term renal sequelae, with mortality rates of 3-5% for typical HUS.

Commonly Confused Points

Study Tips